- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04052204
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase 1b/ Phase 2 Design
Phase 1b will be the sequential dose-finding study.
Once the Phase 1b component is completed, Phase 2 will be initiated to further evaluate the safety and anti-tumor activity across combinations of therapy.
Combination A will enroll participants with SCCHN.
Combination B and C will enroll participants with mCRPC
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Antwerpen
-
Wilrijk, Antwerpen, Belgium, 2610
- GZA Ziekenhuizen campus Sint-Augustinus
-
-
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 02-781
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spain, 08023
- Hospital Quirón Barceloma
-
-
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be ≥ 18 years old.
- Participants with SCCHN or mCRCP.
- Participants must have histological diagnosis of solid tumors and provide tumor tissue.
- Measurable disease by RECIST v1.1 with at least 1 measurable lesion.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
- Adequate bone marrow, renal and liver function
- Highly effective contraceptive use by men with the ability to father a child or women of childbearing potential.
- A WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) at C1D1.
- Signed and dated informed consent.
Exclusion Criteria:
- Known prior severe hypersensitivity to investigational products or any component in their formulations, including known severe hypersensitivity reactions to monocolonal antibodies.
- Known history of: immune-mediated colitis, inflammatory bowel disease, pneumonitis, or pulmonary fibrosis.
- Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
- Prior organ transplantation including allogenic stem cell transplantation.
- Vaccination within 4 weeks prior to C1D1 and while on trial is prohibited except for administration of inactivated vaccines.
- Known symptomatic brain lesions requiring steroids.
- Known history of testing positive for human immunodeficiency virus (HIV or known acquired immunodeficiency syndrome (AIDS).
- Positive HBV surface antigen or HCV test indicating acute or chronic infection..
- Active infection requiring systemic therapy
- Clinically significant (i.e., active) cardiovascular disease including the following: documented left ventricular ejection fraction (LVEF) <50% by ECHO/MUGA; cerebral vascular accident/stroke or transient ischemic attack; myocardial infarction; unstable angina; congestive heart failure or serious cardiac arrhythmia (uncontrolled, clinically significant) requiring medication.
- Diagnosis of any other malignancy within 2 years prior to C1D1, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix and for Combination A only, low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g., surgery, radiation, or castration) or adequately treated prostate cancer.
- Current use of immunosuppressive medication at the time of study enrollment.
- Major surgery within 4 weeks prior to study enrollment.
- Conditions that may impair intake or absorption such as inability to swallow capsules or tablets; known malabsorption syndrome; or baseline diarrhea ≤ Grade 1.
- Participation in other studies involving investigational drug(s) within 2 weeks prior to C1D1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination A
Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck
|
Investigational fully human anti-PD-L1 monoclonal antibody
Other Names:
Investigational CD122-biased cytokine agonist
Other Names:
|
Experimental: Combination B
Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC).
Phase 2 will focus on enrolling participants with DDR defect positive mCRPC.
|
Investigational fully human anti-PD-L1 monoclonal antibody
Other Names:
Investigational CD122-biased cytokine agonist
Other Names:
poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor
Other Names:
|
Experimental: Combination C
Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC
|
Investigational fully human anti-PD-L1 monoclonal antibody
Other Names:
Investigational CD122-biased cytokine agonist
Other Names:
androgen receptor inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Dose Limiting Toxicities (DLT)
Time Frame: Cycle 1 of the treatment period (28 days)
|
DLTs were graded according to NCI- CTCAE version 4.03 and coded using the latest version of Medical Dictionary for Regulatory Activities (MedDRA) preferred term (PT) as event category and MedDRA primary system organ class (SOC) body term as Body System category.
|
Cycle 1 of the treatment period (28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DR)
Time Frame: Approximately 8 months (246 days).
|
DR was defined, for participants with a confirmed Objective Response (OR), as the time from the first documentation of OR to the date of first documentation of progressive disease (PD) or death due to any cause. The documentation of PD was defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. If a subject had not had an event (PD or death), DR was censored at the date of last adequate tumor assessment. As there were no objective responses in the study, no participant met the definition of analysis population. |
Approximately 8 months (246 days).
|
Time to Tumor Response (TTR)
Time Frame: Approximately 8 months (246 days).
|
TTR was defined, for participants with objective response, as the time from the date of first dose of study treatment to the first documentation of objective response (Complete Response or Partial Response) which was subsequently confirmed. As there were no objective responses in the study, no participant met the definition of analysis population. |
Approximately 8 months (246 days).
|
Progression-Free Survival (PFS)
Time Frame: Approximately 8 months (246 days).
|
Progression-Free Survival (PFS) was defined as the time from the date of first dose of study treatment to the date of the first documentation of PD or death due to any cause, whichever occurred first.
PFS data were censored on the date of the last adequate tumor assessment for participants who did not have an event (PD or death), for participants who started new anti-cancer therapy prior to an event, or for participants with an event after two or more missing tumor assessments.
Participants who did not have an adequate baseline tumor assessment or who did not have any adequate post-baseline tumor assessments were censored on the date of first dose of study treatment unless death occurred on or before the time of the second planned tumor assessment, in which case the death was considered an event.
PFS time was summarized using the Kaplan-Meier method.
|
Approximately 8 months (246 days).
|
Overall Survival (OS)
Time Frame: Approximately 8 months (246 days).
|
Overall survival (OS) was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. OS time was summarized using the Kaplan-Meier method. |
Approximately 8 months (246 days).
|
Pharmacokinetic (PK) Parameters - Cmax and Ctrough for Avelumab and NKTR-214
Time Frame: Blood samples were collected on Day 1 and Day 15 in Cycle 1 and Cycle 2 for avelumab. Blood samples were collected on Day 1, Day 3, Day 4 and Day 8 in Cycle 1, Day1 and Day 8 in Cycle 2 for NKTR-214.
|
Cmax was defined as the maximum observed plasma concentration at the end of infusion.
Ctrough was defined as the predose concentration at the end of dosing interval.
|
Blood samples were collected on Day 1 and Day 15 in Cycle 1 and Cycle 2 for avelumab. Blood samples were collected on Day 1, Day 3, Day 4 and Day 8 in Cycle 1, Day1 and Day 8 in Cycle 2 for NKTR-214.
|
Number of Participants With Positive Anti-Drug Antibody (ADA) Results
Time Frame: Day 1 of Cycle 1, 2 and end of treatment (EOT).
|
ADA against avelumab and NKTR-214 in serum samples was determined and reported separately for ADA never-positive, ADA ever-positive participants, baseline ADA positive, treatment-boosted ADA, treatment-induced ADA, transient ADA response, persistent ADA response.
For all participants, blood for ADA samples was drawn from the contralateral arm of the avelumab and NKTR-214 infusion.
|
Day 1 of Cycle 1, 2 and end of treatment (EOT).
|
Number of Participants With Positive Neutralizing Antibody (nAb) Results
Time Frame: Day 1 of Cycle 1, 2 and EOT
|
nAb in serum samples was determined and reported separately for nAb never-positive, nAb ever-positive, baseline nAb positive, treatment-induced nAb, transient nAb response, persistent nAb response.
|
Day 1 of Cycle 1, 2 and EOT
|
PD-L1 Expression Level in Baseline and On-treatment Tumor Tissue
Time Frame: On-treatment biopsy is required to be collected on Cycle 1 between Days 9 and 14 for participants in Combination A.
|
PD-L1 expression level in baseline tumor tissue, and in on-treatment tumor tissue was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and/or inflammatory cells in regions of interest.
PD-L1 expression level in baseline tumor tissue and in on-treatment tumor tissue were under pathological analyses, assisted by image analysis.
Participants were classified as positive or negative according to scoring algorithms and cut-offs established from internal or external sources.
|
On-treatment biopsy is required to be collected on Cycle 1 between Days 9 and 14 for participants in Combination A.
|
Number of Participants With Treatment-Emergent Adverse Events(TEAEs), Serious TEAEs, TEAEs Leading to Death and Infusion-Related Reactions (IRRs) During On-treatment Period
Time Frame: Approximately 6 months (190 days)
|
Adverse events (AEs) were any untoward medical occurrences in a participant or clinical study participants, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Treatment-emergent adverse events (TEAEs) were those events with onset dates occurring during the on-treatment period.
On-treatment period was defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment).
A Serious Adverse Event (SAE) was defined as any untoward medical occurrence that, at any dose: a. Results in death, b.
Was life-threatening, c.
Required inpatient hospitalization or prolongation of existing hospitalization, d.
Resulted in persistent disability/incapacity, e. Was a congenital anomaly/birth defect.
Causality to study treatment was determined by the investigator.
|
Approximately 6 months (190 days)
|
Number of Participants With Laboratory Abnormalities With NCI-CTCAE Grade >= 3 - Safety Analysis Set
Time Frame: Day 1, Day 15 of each treatment cycle
|
Liver Function Tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBILI) were used to assess possible drug induced liver toxicity.
The number of participants with at least one of the following laboratory results were summarized below: 1. (ALT ≥3 × ULN or AST ≥3 × ULN) post-baseline.
2. TBILI ≥2 × ULN post-baseline.
3. (ALP ≤2 × ULN or missing) post-baseline.
|
Day 1, Day 15 of each treatment cycle
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Poly(ADP-ribose) Polymerase Inhibitors
- Avelumab
- Talazoparib
Other Study ID Numbers
- B9991040
- 2019-001358-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of the Head and Neck (SCCHN)
-
Massachusetts General HospitalDana-Farber Cancer Institute; Genentech, Inc.; Emory University; University of... and other collaboratorsTerminatedSquamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Hoffmann-La RocheActive, not recruitingLocally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
-
British Columbia Cancer AgencyWithdrawnLocally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)Canada
-
PfizerCompletedSquamous Cell Carcinoma of the Head and Neck (SCCHN)United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
-
University of Michigan Rogel Cancer CenterTerminatedSquamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Glenn J. HannaSecura Bio, Inc.Active, not recruitingMetastatic Head and Neck Cancer | Advanced Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Advanced Head and Neck CancerUnited States
-
Incyte CorporationActive, not recruitingAdvanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Gastrointestinal (GI) MalignanciesUnited States, Netherlands, Spain, United Kingdom, Belgium, Austria
-
AstraZenecaCompletedRecurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHNUnited States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
-
Merck KGaA, Darmstadt, GermanyMerck Ltd., IndiaTerminatedUnresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHNIndia
Clinical Trials on avelumab
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Clinique Neuro-OutaouaisCompletedGlioblastoma Multiforme of BrainCanada
-
Promontory Therapeutics Inc.Pfizer; EMD SeronoCompletedNon-Small Cell Lung Cancer (NSCLC)United States, Switzerland
-
Vaccinex Inc.University of RochesterRecruitingMetastatic Pancreatic AdenocarcinomaUnited States
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyActive, not recruitingLymphoma, Extranodal NK-T-CellKorea, Republic of
-
4SC AGMerck KGaA, Darmstadt, GermanyWithdrawn
-
Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsGermany
-
AHS Cancer Control AlbertaEMD Serono; Alberta Cancer FoundationRecruitingSquamous Cell Carcinoma of the SkinCanada
-
McGill University Health Centre/Research Institute...RecruitingGastric Adenocarcinoma | Esophageal AdenocarcinomaCanada
-
PfizerNot yet recruitingUrinary Bladder Neoplasms | Bladder Cancer | Urothelial Carcinoma | Bladder TumorsCanada